PURPOSE OF REVIEW: Fibroblast growth factor receptor (FGFR) signalling, especially induced by FGFR3, is a crucial factor in the pathogenesis of urothelial carcinoma and was therefore extensively studied over the last decades. In this review, we summarize the most relevant findings of the past two years. RECENT FINDINGS: Recent studies support the concept that FGFR3 mediates a pathway of urothelial carcinogenesis associated with low malignant potential. FGFR3 may represent a highly accurate biomarker for diagnosis and prediction of recurrence, progression or therapy response. The pan FGFR-inhibitor erdafitinib was recently approved for urothelial carcinoma, whereas several other FGFR-targeted drugs are currently undergoing clinical trials. SUMMARY: Numerous recent studies focus on the role of FGFR3 in different urothelial carcinoma subtypes and its potential clinical application as noninvasive biomarker, as well as therapeutic target.

Department of Cancer Medicine Gustave Roussy Institute INSERM 981 Cancer Campus Grand Paris University of Paris Saclay Villejuif France

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology University of Jordan Amman Jordan

Department of Urology University of Texas Southwestern Dallas Texas USA

Department of Urology Weill Cornell Medical College New York USA

Institute for Urology and Reproductive Health 1 M Sechenov 1st Moscow State Medical University Moscow Russia

Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran

See more in PubMed

Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10:116–129.

Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005; 16:233–247.

Porta R, Borea R, Coelho A, et al. FGFR a promising druggable target in cancer: molecular biology and new drugs. Crit Rev Oncol Hematol 2017; 113:256–267.

di Martino E, Tomlinson DC, Knowles MA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012; 2012:429213.

Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23:18–20.

Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001; 158:1955–1959.

van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61:1265–1268.

Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63:8108–8112.

Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5:713–725.

Pandith AA, Shah ZA, Siddiqi MA. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol Semin Orig Investig 2013; 31:398–406.

Inamura K. Bladder cancer: new insights into its molecular pathology. Cancers (Basel) 2018; 10:100.

Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009; 69:4613–4620.

Tomlinson DC, Knowles MA. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 2010; 177:2379–2386.

Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007; 25:581–593.

Iyer G, Milowsky MI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol Oncol Semin Orig Investig 2013; 31:303–311.

di Martino E, Alder O, Hurst CD, Knowles MA. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer. Sci Rep 2019; 9:5740.

Mao W, Huang X, Wang L, et al. Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression. J Exp Clin Cancer Res 2019; 38:169.

Mahe M, Dufour F, Neyret-Kahn H, et al. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med 2018; 10:

Foth M, Ismail NFB, Kung JSC, et al. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation. J Pathol 2018; 246:331–343.

Xie X, Lin J, Zhong Y, et al. FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells. Exp Ther Med 2019; 18:1226–1234.

Cancer Genome Atlas Research Network TCGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507:315–322.

Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 2017; 171:540–556.e25.

Sfakianos JP, Cha EK, Iyer G, et al. Genomic characterization of upper tract urothelial carcinoma. Eur Urol 2015; 68:970–977.

Nassar AH, Umeton R, Kim J, et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res 2019; 25:2458–2470.

Audenet F, Isharwal S, Cha EK, et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 2019; 25:967–976.

Kim YS, Kim K, Kwon GY, et al. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. BMC Urol 2018; 18:68.

Eich ML, Rodriguez Pena MD, Springer SU, et al. Incidence and distribution of UroSEEK gene panel in a multiinstitutional cohort of bladder urothelial carcinoma. Mod Pathol 2019; 32:1544–1550.

Jungels C, Martinez Chanza N, Albisinni S, et al. Interest of next-generation sequencing in BCG-treated high-risk bladder cancer. Progrès en Urol 2018; 28:344–350.

Garczyk S, Ortiz-Brüchle N, Schneider U, et al. Next-generation sequencing reveals potential predictive biomarkers and targets of therapy for urothelial carcinoma in situ of the urinary bladder. Am J Pathol 2019; 0:

Apollo A, Ortenzi V, Scatena C, et al. Molecular characterization of low grade and high grade bladder cancer. PLoS One 2019; 14:e0210635.

Lott S, Wang M, Zhang S, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol 2009; 22:627–632.

van Rhijn BW, Montironi R, Zwarthoff EC, et al. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198:245–251.

Isharwal S, Hu W, Sarungbam J, et al. Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol 2019; 248:ath.5261.

Hernández S, López-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24:3664–3671.

van Rhijn BW, van der Kwast TH, Liu L, et al. The FGFR3 mutation is related to favorable pt1 bladder cancer. J Urol 2012; 187:310–314.

van Kessel KE, van der Keur KA, Dyrskjøt L, et al. Molecular markers increase precision of the European Association of Urology nonmuscle-invasive bladder cancer progression risk groups. Clin Cancer Res 2018; 24:1586–1593.

Gómez-Román JJ, Saenz P, Molina M, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005; 11:459–465.

Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213:91–98.

Akanksha M, Sandhya S. Role of FGFR3 in urothelial carcinoma. Iran J Pathol 2019; 14:148–155.

Breyer J, Wirtz RM, Erben P, et al. High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma. Clin Genitourin Cancer 2018; 16:248–256.e2.

Geelvink M, Babmorad A, Maurer A, et al. Diagnostic and prognostic implications of FGFR3-high/Ki67-high papillary bladder cancers. Int J Mol Sci 2018; 19:

Zhu F, Zhang Y, Shi L, et al. Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery. Medicine (Baltimore) 2019; 98:e16451.

Ward DG, Gordon NS, Boucher RH, et al. Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for noninvasive diagnosis and risk stratification. BJU Int 2019; 124:532.

Hayashi Y, Fujita K, Matsuzaki K, et al. Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci 2019; 110:1771–1779.

Borkowska EM, Traczyk-Borszyńska M, Kutwin P, et al. Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer. Urol Oncol Semin Orig Investig 2019; 37:907–915.

Yang Z, Zhang R, Ge Y, et al. Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy. EBioMedicine 2018; 35:198–203.

Lerner SP, McConkey DJ, Hoadley KA, et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bl Cancer (Amsterdam, Netherlands) 2016; 2:37–47.

Tan TZ, Rouanne M, Tan KT, et al. Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors. Eur Urol 2019; 75:423–432.

Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020; 77:420–433.

de Jong JJ, Liu Y, Robertson AG, et al. Long noncoding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Med 2019; 11:60.

Bernardo C, Eriksson P, Marzouka N, et al. Molecular pathology of the luminal class of urothelial tumors. J Pathol 2019; 249:308–318.

Robinson BD, Vlachostergios PJ, Bhinder B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun 2019; 10:2977.

Casadei C, Dizman N, Schepisi G, et al. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol 2019; 11:1758835919890285.

Markham A. Erdafitinib: first global approval. Drugs 2019; 79:1017–1021.

Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019; 381:338–348.

Ibrahim T, Gizzi M, Bahleda R, Loriot Y. Clinical development of FGFR3 inhibitors for the treatment of urothelial cancer. Bl Cancer 2019; 5:87–102.

Pal SK, Rosenberg JE, Hoffman-Censits JH, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov 2018; 8:812–821.

Schuler M, Cho BC, Sayehli CM, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019; 20:1454–1466.

Perera TP, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther 2017; 16:1010–1020.

Zheng Z, Ji H, Zong W, et al. Construction and characterization of immunoliposomes targeting fibroblast growth factor receptor 3. AMB Express 2019; 9:150.

Hortelão AC, Carrascosa R, Murillo-Cremaes N, et al. Targeting 3D bladder cancer spheroids with urease-powered nanomotors. ACS Nano 2019; 13:429–439.

Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis